{"id":"W4233817719","doi":"10.1056/nejmoa1602773","title":"Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1806,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; University of Calgary; Robarts Clinical Trials; Western University","funders":"Janssen Research and Development; Merck Sharp and Dohme; UCB Pharma; Sun Pharma; Tillotts Pharma; Amgen; Seres Therapeutics; Celltrion; Genentech; Janssen Scientific Affairs; Celgene; Biogen; Gilead Sciences; Dr. Falk Pharma; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ustekinumab; Medicine; Crohn's disease; Maintenance therapy; Interleukin 23; Monoclonal antibody; Monoclonal; Disease; Immunology; Interleukin; Internal medicine; Antibody; Cytokine; Chemotherapy; Adalimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001162292,0.0003399503,0.001245856,0.0004127088,0.0003345528,0.000408048,0.0004340002,0.0005469864,0.001426222],"category_scores_gemma":[0.000907066,0.0001203659,0.0004105342,0.0005187095,0.0003728107,0.0003520315,0.0002266884,0.001522569,0.0002893443],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004241903,"about_ca_system_score_gemma":0.0004630549,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004801883,"about_ca_topic_score_gemma":0.001089294,"domain_scores_codex":[0.9995371,0.0001966859,0.00004446709,0.00004742019,0.00007833709,0.00009613295],"domain_scores_gemma":[0.9994684,0.0001685785,0.00006688045,0.00005816113,0.00005060346,0.0001874614],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1840715,0.01908116,0.01614534,0.0009038129,0.0005510275,0.0008950416,0.0005254316,0.00105886,0.09062426,0.0005324511,0.001572323,0.6840389],"study_design_scores_gemma":[0.08769397,0.688191,0.1255031,0.000298882,0.001333728,0.002925348,0.0003166789,0.002329744,0.07265817,0.0003481738,0.01833487,0.00006636172],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.984542,0.01083255,0.0005463032,0.0002533776,0.0001094157,0.0004059047,0.0001827107,0.00008089897,0.003046959],"genre_scores_gemma":[0.9949421,0.002486167,0.0008882531,0.0001562507,0.000105776,0.0002746086,0.0002760825,0.000009029605,0.0008616592],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001426222,"threshold_uncertainty_score":0.006146848,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01067286993960359,"score_gpt":0.2590847257424746,"score_spread":0.248411855802871,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}